Pf Prism Company Profile
✉ Email this page to a colleague
What is the competitive landscape for PF PRISM, and when can generic versions of PF PRISM drugs launch?
PF PRISM has sixteen approved drugs.
There are twenty-nine US patents protecting PF PRISM drugs.
There are six hundred and twelve patent family members on PF PRISM drugs in sixty-six countries and seventy-two supplementary protection certificates in eighteen countries.
Summary for Pf Prism
International Patents: | 612 |
US Patents: | 29 |
Tradenames: | 11 |
Ingredients: | 11 |
NDAs: | 16 |
Patent Litigation for Pf Prism: | See patent lawsuits for Pf Prism |
Drugs and US Patents for Pf Prism
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Pf Prism Cv | BOSULIF | bosutinib monohydrate | CAPSULE;ORAL | 217729-002 | Sep 26, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Pf Prism Cv | XALKORI | crizotinib | CAPSULE, PELLETS;ORAL | 217581-003 | Sep 7, 2023 | RX | Yes | Yes | 7,858,643 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Pf Prism Cv | XALKORI | crizotinib | CAPSULE, PELLETS;ORAL | 217581-002 | Sep 7, 2023 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Pf Prism Cv | BOSULIF | bosutinib monohydrate | TABLET;ORAL | 203341-001 | Sep 4, 2012 | RX | Yes | Yes | 7,767,678*PED | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Pf Prism Cv | XALKORI | crizotinib | CAPSULE, PELLETS;ORAL | 217581-002 | Sep 7, 2023 | RX | Yes | No | 7,230,098 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Pf Prism Cv | BOSULIF | bosutinib monohydrate | TABLET;ORAL | 203341-003 | Oct 27, 2017 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Pf Prism Cv | BOSULIF | bosutinib monohydrate | TABLET;ORAL | 203341-002 | Sep 4, 2012 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Pf Prism
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Pf Prism Cv | RAPAMUNE | sirolimus | TABLET;ORAL | 021110-002 | Aug 22, 2002 | 5,212,155*PED | ⤷ Try a Trial |
Pf Prism Cv | RAPAMUNE | sirolimus | SOLUTION;ORAL | 021083-001 | Sep 15, 1999 | 5,100,899*PED | ⤷ Try a Trial |
Pf Prism Cv | TORISEL | temsirolimus | SOLUTION;INTRAVENOUS | 022088-001 | May 30, 2007 | 8,455,539*PED | ⤷ Try a Trial |
Pf Prism Cv | BOSULIF | bosutinib monohydrate | TABLET;ORAL | 203341-003 | Oct 27, 2017 | 6,002,008 | ⤷ Try a Trial |
Pf Prism Cv | TYGACIL | tigecycline | POWDER;INTRAVENOUS | 021821-001 | Jun 15, 2005 | RE40183 | ⤷ Try a Trial |
Pf Prism Cv | VFEND | voriconazole | FOR SUSPENSION;ORAL | 021630-001 | Dec 19, 2003 | 5,116,844 | ⤷ Try a Trial |
Pf Prism Cv | RAPAMUNE | sirolimus | TABLET;ORAL | 021110-002 | Aug 22, 2002 | 5,403,833*PED | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for PF PRISM drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Oral Suspension | 40 mg/mL | ➤ Subscribe | 2010-10-08 |
➤ Subscribe | Injection | 25 mg/mL, 1.8 mL vial | ➤ Subscribe | 2011-05-25 |
➤ Subscribe | Tablets | 0.5 mg | ➤ Subscribe | 2010-08-25 |
➤ Subscribe | Extended-release Tablets | 25 mg | ➤ Subscribe | 2015-05-08 |
➤ Subscribe | Tablets | 1 mg and 5 mg | ➤ Subscribe | 2018-02-23 |
➤ Subscribe | Tablets | 400 mg | ➤ Subscribe | 2018-10-15 |
➤ Subscribe | Tablets | 50 mg and 200 mg | ➤ Subscribe | 2008-04-14 |
➤ Subscribe | For Injection | 50 mg per vial | ➤ Subscribe | 2009-06-15 |
➤ Subscribe | Tablets | 1 mg and 2 mg | ➤ Subscribe | 2009-12-17 |
➤ Subscribe | Extended-release Tablets | 50 mg and 100 mg | ➤ Subscribe | 2012-02-29 |
➤ Subscribe | Tablets | 0.5 mg and 1 mg | ➤ Subscribe | 2010-05-10 |
➤ Subscribe | Tablets | 5 mg | ➤ Subscribe | 2016-11-07 |
➤ Subscribe | Tablets | 100mg and 500mg | ➤ Subscribe | 2016-09-06 |
➤ Subscribe | For Injection | 200 mg/vial | ➤ Subscribe | 2008-09-12 |
International Patents for Pf Prism Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
European Patent Office | 3398597 | ⤷ Try a Trial |
South Korea | 20050026025 | ⤷ Try a Trial |
World Intellectual Property Organization (WIPO) | 0102369 | ⤷ Try a Trial |
Australia | 782092 | ⤷ Try a Trial |
World Intellectual Property Organization (WIPO) | 2006128150 | ⤷ Try a Trial |
Guatemala | 200400183 | ⤷ Try a Trial |
Taiwan | 200901989 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Pf Prism Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0536515 | 2006/030 | Ireland | ⤷ Try a Trial | PRODUCT NAME: TIGECYCLINE OR A PHARMACOLOGICALLY ACCEPTABLE ORGANIC OR INORGANIC SALT OR METAL COMPLEX THEREOF; REGISTRATION NO/DATE: EU/1/06/336/001 20060424 |
0536515 | C300244 | Netherlands | ⤷ Try a Trial | PRODUCT: TIGECYCLINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF METAALCOMPLEX, IN HET BIJZONDER TIGECYCLINE; FIRST REGISTRATION, DATE: EU/1/06/336/001, 20060424 |
1218348 | CR 2013 00010 | Denmark | ⤷ Try a Trial | PRODUCT NAME: AXITINIB, EVENTUELT I FORM AF ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/12/777/001-006 20120903 |
1218348 | PA2013003,C1218348 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: AXITINIBUM; REGISTRATION NO/DATE: EU/1/12/777/001 - EU/1/12/777/006 20120903 |
1218348 | 2013C/015 | Belgium | ⤷ Try a Trial | PRODUCT NAME: AXITINIB; AUTHORISATION NUMBER AND DATE: EU/1/12/777/001 20120905 |
0648494 | 01C0037 | France | ⤷ Try a Trial | PRODUCT NAME: SIROLIMUS; NAT. REGISTRATION NO/DATE: EU/1/01/171/001-005 20010313; FIRST REGISTRATION: IKS55243 20000926 |
1666481 | 132017000095300 | Italy | ⤷ Try a Trial | PRODUCT NAME: TOFACITINIB, OPZIONALMENTE NELLA FORMA DI UN SALE FARMACEUTICAMENTE ACCETTABILE, COMPRENDENTE IL SALE CITRATO(XELJANZ); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/17/1178/001-004, 20170324 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.